SCHEMBL4523072

SCHEMBL4523072

CC(C)C(=O)[CH]N1CCNCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
CA2 P00918 2/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
CHKA P35790 1/20 0.34
SIGMAR1 Q99720 2/20 0.33
CHRNB2 P17787 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
CHRNB3 Q05901 1/20 0.33
CHRNA6 Q15825 1/20 0.33
OPRD1 P41143 4/20 0.33
CYP1A2 P05177 1/20 0.33
KMT2A Q03164 2/20 0.30
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706425 0.77 CA2 (0.38) CHRM5CHRM3CA2CA12CA1
SCHEMBL1821635 0.73 CA2 (0.38) CA2CA12CA1CA9CHKA
SCHEMBL1819295 0.72 OPRD1 (0.36) CHRM5CHRM3CA2CA12CA1
SCHEMBL1820781 0.72 CA2 (0.34) CHRM5CHRM3CA2CA12CA1
SCHEMBL3600027 0.72 MEN1 (0.39) CHRM5CHRM3CA2CA12CA1
SCHEMBL3591817 0.72 TSHR (0.46) CHRM5CHRM3KMT2AMEN1ALDH1A1
SCHEMBL4376942 0.69 CHRM5 (0.32) CHRM5CHRM3SIGMAR1KMT2AMEN1
SCHEMBL4365547 0.68 CA2 (0.48) CHRM5CHRM3CA2CA12CA1
SCHEMBL188170 0.68 CA2 (0.48) CHRM5CHRM3CA2CA12CA1
SCHEMBL3590883 0.68 HCAR2 (0.38) CA2CA12CA1CA9SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2009-08-13 US claimed
CN-101374842-A Azepinoindole derivatives as pharmaceutical agents EXELIXIS INC (US) 2009-02-25 CN claimed
EP-1963331-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2008-09-03 EP claimed
WO-2007070796-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2007-06-21 WO claimed
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2009-08-13 US disclosed
CN-101374842-A Azepinoindole derivatives as pharmaceutical agents EXELIXIS INC (US) 2009-02-25 CN disclosed
EP-1963331-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2008-09-03 EP disclosed
WO-2007070796-A1 AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203577-A1 Azepinoindole Derivatives As Pharmaceutical Agents NR1H4, NR1I2, GPBAR1 CHRM5 383/4885CHRM3 291/4885CA2 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.